Fifty years of clinical research by the Leukemia Committee of the Cancer and Leukemia Group B

Clinical Cancer Research

Volumn 12, Issue 11 II, 2006, Pages

  Larson, Richard A ^a   Stone, Richard M ^b   Mayer, Robert J ^b   Schiffer, Charles A ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; AZACITIDINE; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMATINIB; INTERFERON; INTERLEUKIN 2; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; NELARABINE; PREDNISONE; PROTEIN BCL 2; RETINOIC ACID; RITUXIMAB; VALSPODAR; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER; CHEMOTHERAPY; CHROMOSOME ABERRATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG RESPONSE; DRUG TOXICITY; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; MUCOSA; MYELODYSPLASTIC SYNDROME; MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; REVIEW; SOLID TUMOR;

BIOMEDICAL RESEARCH; CLINICAL TRIALS; HISTORY, 20TH CENTURY; HUMANS; LEUKEMIA; MEDICAL ONCOLOGY; SOCIETIES, MEDICAL;

EID: 33745199587     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-9001     Document Type: Review

References (30)

1. Keating P, Cambrosio A. From screening to clinical research: the cure of leukemia and the early development of the cooperative oncology groups, 1955-1966. Bull Hist Med 2002;76:299-334.
2. Frei E, Holland JF, Schneiderman MA, et al. A comparative study of two regimens of combination chemotherapy in acute leukemia [ALGB study 01]. Blood 1958;13:1126-48.
3. Freireich EJ, Gehan E, Frei E III, et al. The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute leukemia: a model for evaluation of other potentially useful therapy. From the Acute Leukemia Group B [ALGB study 03]. Blood 1963;21:699-716.
4. Frei E, Freireich EJ, Gehan E, et al. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate [ALGB study 02]. Blood 1961;18:431-54.
5. George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 1996;14:1364-70.
6. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: a CALGB study [CALGB study 7721]. Blood 1982;60:454-62.
7. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia [CALGB 8525]. N Engl J Med 1994;331:896-903.
8. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype [CALGB 8525 and 8461]. Cancer Res 1998;58:4173-9.
9. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia [CALGB 8923]. N Engl J Med 1995;332:1671-7.
10. Stone RM, Berg DT, George SL, et al. Post-remission therapy in older patients with de novo acute myeloid leukemia (AML): a randomized trial of mitox-antrone/intermediate dose cytarabine versus standard dose cytarabine (CALGB study 8923). Blood 2001;98:548-53.
11. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood 2005;105:3420-7.
12. Lee EJ, George SL, Caligiuri MA, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B Study 9420. J Clin Oncol 1999;17:2831-9.
13. Baer MR, George SL, Dodge RK, et al. Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with AML: Cancer and Leukemia Group B study 9720. Blood 2002;100:1224-32.
14. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia <60 years old: final induction results of CALGB study 9621. J Clin Oncol 2004;22:4290-301.
15. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia [CALGB 9191]. N Engl J Med 1997;337:1021-8.
16. Tallman MS, Anderson JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia: long term outcome and prognosis factor analysis from the North American Intergroup protocol [CALGB 9191]. Blood 2002;100:4298-302.
17. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B (9221). J Clin Oncol 2002;20:2429-40.
18. Kornblith AB, Herndon JE II, Silverman LR, et al. The impact of 5-azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study [CALGB 9221]. J Clin Oncol 2002;20:2441-52.
19. Gottlieb AJ, Weinberg V, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: A prospective randomized trial by CALGB [CALGB 7612]. Blood 1984;64:267-74.
20. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood 1995;85:2025-37.
21. Larson RA, Dodge RK, Linker C, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB Study 9111. Blood 1998;92:1556-64.
22. Wetzler M, Dodge RK, Mrozek KA, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia-the Cancer and Leukemia Group B experience [CALGB 8461]. Blood 1999;93:3983-93
23. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B study 9251. Cancer 2004;100:1438-48.
24. Rai KR, Peterson BL, Kolitz JE, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia [CALGB 9011]. N Engl J Med 2000;343:1750-7.
25. Byrd JC, Peterson BL, Morrison V, et al. Randomized phase II study of concurrent versus sequential treatment of rituximab with fludarabine in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: superior complete response rates with concurrent therapy: results of CALGB 9712. Blood 2003;101:6-14.
26. Byrd JC, Rai KR, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.
27. Ozer H, George SL, Schiffer CA, et al. Prolonged subcutaneous administration of recombinant α-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: CALGB study 8583. Blood 1993;82:2975-84.
28. Silver RT, Peterson BL, Szatrowski TP, et al. Treatment of the chronic phase of CML with an intermittent schedule of recombinant interferon α-2b and cytarabine: CALGB 9013. Leuk Lymphoma 2003;44:39-48.
29. Stock W, Westbrook CA, Peterson B, et al. Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study [CALGB 9013]. J Clin Oncol 1997;15:26-36.
30. Hensley ML, Silver RT, Peterson BL, Larson RA, Szatrowski TP. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon-α-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000;18:1301-8.